The 4.83 price-to-book multiple sits above ICE (3.21) and CME (3.83) despite Nasdaq's 4.5% ROE trailing theirs by 900-1,100bp, which suggests the market is capitalising fee-based recurring revenue streams at fintech economics rather than exchange economics. The implied ROTCE required to justify this multiple appears difficult to reach while tangible book value per share remains negative, so the valuation rests on the durability of index licensing and compliance software pricing rather than on current book returns. Note that the ratio table reports P/B of 21.31 for 2026Q3 against a stated 4.83; this inconsistency warrants confirmation before the multiple is used in a comps model.

Decomposing DuPont, ROA expanded from 0.7% to 2.0% while the equity multiplier compressed from roughly 2.8x to 2.3x, meaning profitability quality improved even as a growing capital base acted as a drag — a favourable combination versus banks that lean on leverage to manufacture ROE. However, at 4.5% ROE the franchise still converts less than half the return of CME or Cboe, so the gap appears structural (heavy intangibles from Adenza depressing the equity base's earning power) rather than cyclical. Fee income at 103.3% of revenue confirms earnings quality rests entirely on subscription, index and transaction pricing, with negative net interest income subtracting rather than contributing.

The NIM inflection from 0.0% to -0.3% in 2025Q4 coincides with the Adenza close, which may indicate a permanent shift in interest expense rather than a rate-cycle artefact — consistent with the prior finding that net interest income flipped to a persistent $76-81M quarterly deficit. The efficiency ratio's swing from a 12.9-17.9% band to a 25.4-38.3% range suggests operating leverage is now working in reverse: costs step up ahead of the fee growth they are meant to support. Investors should monitor whether the ratio stabilises near the 32.5% level as integration completes, because a sustained reading above 35% would undermine the margin-expansion thesis underpinning the current multiple.

Explicit CET1, Tier 1 and total capital ratios are not available in the supplied data, so regulatory headroom for capital return cannot be assessed here; equity-to-assets at 44% is the only capital proxy, and it suggests the buffer is expanding faster than it is being deployed. The negative and only slowly improving tangible book (from -$17.70 to -$14.82) implies goodwill and intangibles from the $10.5bn Adenza transaction dominate the equity structure, which would make buybacks and dividends funded from a book that offers little tangible protection. The reported debt/equity of 0.81% remains difficult to reconcile with the acquisition size, so capital adequacy conclusions should be treated as provisional pending disclosed regulatory ratios.

The profitability gap appears structural rather than cyclical: Cboe and MarketAxess convert 24-26% ROE with efficiency ratios far below Nasdaq's post-integration 32.5%, while Nasdaq's fee mix above 100% of revenue means it has no offsetting spread income to cushion integration costs. Conversely, Nasdaq leads on the durability of its revenue mix — the highest fee-income dependence in the group — which may explain why its P/E premium to ICE (33.19 vs 28.20) persists despite inferior returns. The divergence that matters is whether the ROE gap closes as Adenza and Verafin scale; if it does not, the multiple premium relative to CME and ICE would be difficult to defend.